
    
      PL-doxorubicin 35-40 mg/m(2) and epirubicin 70mg/m(2) were given on day 1 in combination with
      standard dosage of prednisone, vincristine, cyclophosphamide (according to CHOP regimen)
      every 21days for six courses. The choice to adopt the dosage of 30 mg/m2(instead of 50 mg/m2
      of conventionaldoxorubicin) was based on pharmacokinetic data and on the results of previous
      studies in lymphoma.Rituximab 375 mg/m2 was given on day 0 in subsequent courses of therapy.
      Granulocyte colony-stimulating factor was given in the presence of grade 4 neutropenia or
      febrile neutropenia until hematological recovery. Treatment was stopped if lymphoma
      progressed, the patient refused further participation,or if there was any other intercurrent
      clinical condition or adverse event.
    
  